Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease. The FDA IND clearance follows the December…
Sanofi is paying $80 million upfront and pledging up to $960 million in milestones for exclusive worldwide rights to ADEL-Y01, a Phase 1 tau antibody from…
ADEL closed ~49 billion won (~$36M) pre-IPO round, exceeding its 40B-won target ~23%, and aims to complete a KOSDAQ technology-special listing within…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Sanofi obtained an exclusive worldwide license to ADEL-Y01, a humanized monoclonal antibody selectively targeting tau acetylated at lysine-280 (acK280) for Alzheimer's disease, plus related backup compounds. ADEL received an $80M non-refundable upfront payment and is eligible for up to $960M in development and commercial milestones (total up to $1.04B), plus tiered royalties on net sales reaching up to double-digit percentages. ADEL-Y01 is in a global Phase 1a/1b first-in-human study (healthy volunteers plus participants with mild cognitive impairment or mild Alzheimer's disease) under a U.S. FDA IND. ADEL co-developed the asset with Oscotec under a 2020 joint R&D agreement.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / ADEL, Inc. (this deal) | 2025 | $1.0B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2025 deals · Sanofi SA deals · Neurology deals